Conduit Pharmaceuticals (NASDAQ:CDT – Get Free Report) posted its earnings results on Monday. The company reported ($0.07) earnings per share (EPS) for the quarter, reports.
Conduit Pharmaceuticals Trading Up 0.8 %
Shares of NASDAQ CDT opened at $0.15 on Thursday. Conduit Pharmaceuticals has a 52-week low of $0.13 and a 52-week high of $25.00. The company’s 50-day simple moving average is $0.82 and its 200-day simple moving average is $2.27.
Analyst Upgrades and Downgrades
Separately, Berenberg Bank upgraded Conduit Pharmaceuticals to a “strong-buy” rating in a research report on Friday, July 26th.
Conduit Pharmaceuticals Company Profile
Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Further Reading
- Five stocks we like better than Conduit Pharmaceuticals
- Basic Materials Stocks Investing
- Why Meta Could Be A $600 Stock Within Weeks
- Investing in Travel Stocks Benefits
- Conservative Portfolio: Strategies for Stability
- Investing in Commodities: What Are They? How to Invest in Them
- Unlocking Growth: Why Arcos Dorados Belongs in Your Portfolio
Receive News & Ratings for Conduit Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conduit Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
